Syndax Pharmaceuticals Presents Positive Data on Revumenib in Acute Leukemias at ASH Annual Meeting
Revumenib Shows Promising Results in Combination Therapy
Syndax Pharmaceuticals has announced positive data from multiple trials of Revuforj® (revumenib) at the 66th American Society of Hematology (ASH) Annual Meeting. The data reveals an impressive 82% overall response rate (ORR) and a 48% complete response (CR)/CR with partial hematologic recovery (CRh) in the SAVE trial, which studied the combination of revumenib with venetoclax and decitabine/cedazuridine in relapsed/refractory acute myeloid leukemia (AML) patients.
Impressive Results in Expanded Dataset
In addition, the expanded dataset of the Phase 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 showed a 64% ORR and a 23% CR/CRh, with high rates of minimal residual disease (MRD) negativity and the ability to proceed to hematopoietic stem cell transplantation (HSCT). Responses were rapid, durable, and observed across all major subgroups, highlighting the compelling clinical profile of revumenib.
Advancing into Combination Trials
The latest data support the advancement of revumenib into combination trials in the frontline setting. Syndax Pharmaceuticals is optimistic about the potential of revumenib as a single agent and in combination with standard of care agents for the treatment of acute leukemias.
Impact on Individuals and the World
This positive data on revumenib presented by Syndax Pharmaceuticals at the ASH Annual Meeting will have a significant impact on both individuals and the world. For individuals diagnosed with acute leukemias, the promising results of revumenib in combination therapy offer hope for improved outcomes and potentially more effective treatment options. Patients may benefit from rapid and durable responses, as well as the ability to proceed to HSCT following treatment with revumenib.
On a global scale, the development of effective therapies for acute leukemias is crucial in improving overall survival rates and quality of life for patients. The advancement of revumenib into combination trials represents a step forward in the fight against these challenging diseases, offering new possibilities for treatment and potentially changing the standard of care for acute leukemias.
Conclusion
The positive data on revumenib presented by Syndax Pharmaceuticals at the ASH Annual Meeting underscores the potential of this innovative therapy in the treatment of acute leukemias. With impressive response rates and the ability to proceed to HSCT, revumenib shows promise as a valuable addition to the armamentarium of therapies for patients with relapsed/refractory disease. The compelling clinical profile of revumenib supports further investigation in combination trials, paving the way for improved outcomes and advancements in the field of oncology.
